Product Details

Uniprot No.

Target Names

Alternative Names

Antigen identified by monoclonal antibody 1D8 antibody; Antigenic surface determinant protein OA3 antibody; CD 47 antibody; CD47 antibody; CD47 antigen (Rh-related antigen; integrin-associated signal transducer) antibody; CD47 antigen antibody; CD47 glycoprotein antibody; CD47 molecule antibody; CD47_HUMAN antibody; IAP antibody; Integrin Associated Protein antibody; Integrin associated signal transducer antibody; Integrin-associated protein antibody; Leukocyte surface antigen CD47 antibody; MER 6 antibody; MER6 antibody; OA 3 antibody; OA3 antibody; OTTHUMP00000041152 antibody; OTTHUMP00000041153 antibody; Protein MER6 antibody; Rh related antigen antibody; Surface antigen identified by monoclonal antibody 1D8 antibody

Species Reactivity

Human

Immunogen

Recombinant Human CD47 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

4E5

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, FC

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Protocols

ELISA Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

CD47, also known as integrin-associated protein (IAP), serves as a critical "don't eat me" signal on cell surfaces, interacting with signal regulatory protein alpha (SIRPα) on macrophages to inhibit phagocytosis. This pathway has emerged as a compelling target in cancer immunotherapy research, as many tumor cells exploit CD47 overexpression to evade immune surveillance. Understanding CD47 biology is essential for researchers investigating immune checkpoint mechanisms, tumor microenvironment interactions, and novel therapeutic strategies.

This recombinant monoclonal antibody against human CD47, clone 4E5, offers the reproducibility and consistency that demanding experimental workflows require. Produced using recombinant technology with a defined human IgG1 isotype, this antibody eliminates the lot-to-lot variability that can compromise longitudinal studies and multi-site collaborations. The sequence-defined nature of recombinant production ensures you can confidently compare results across experiments and publications.

Validation data demonstrates robust performance in functional applications. In ELISA testing, immobilized human CD47 protein showed strong binding activity with an EC50 of 1.343-1.561 ng/mL, indicating high sensitivity for quantitative detection. Flow cytometry validation using transfected Human DLL3 and CD47 CT26 stable cells confirmed specific detection of CD47-expressing populations compared to untransfected controls, with recommended dilutions of 1:50-1:200 providing flexibility for optimization in your specific experimental system.

Supplied in a glycerol-based PBS buffer with Proclin 300 preservative, this affinity-purified antibody maintains stability when stored at -20°C or -80°C. Whether you are investigating macrophage-tumor cell interactions, screening therapeutic candidates targeting the CD47-SIRPα axis, or characterizing CD47 expression patterns in human samples, this antibody provides a reliable foundation for cancer and immunology research programs.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.

Gene References into Functions

results suggest that cancers can evolve SE to drive CD47 overexpression to escape immune surveillance PMID: 28378740
overexpression of human CD200 in donor pigs could constitute a promising strategy for overcoming xenograft rejection. PMID: 28968355
High CD47 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
CD47 expression is decreased on the surface of erythrocytes in obese subjects. These changes in CD47 expression on the erythrocytes surface may be an adaptive response to hyperfibrinogenemia associated with obesity. PMID: 25914268
Results show that the thrombospondin 1 (TSP1) and its receptor CD47 (CD47) axis selectively regulates NADPH oxidase 1 (Nox1) in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level. PMID: 29042481
CD47 is overexpressed in primary non-small cell lung cancer (NSCLC) tissues and cell lines, suggesting that CD47 is a promising therapeutic target for NSCLC. PMID: 27411490
Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1). PMID: 28393401
Blocking CD47 using antibodies could efficiently induce macrophage-mediated phagocytosis of tumor cells and treat cancers. PMID: 27863402
High CD47 expression is not associated with Fibrolamellar Hepatocellular Carcinoma. PMID: 28801364
TTI-621 (SIRPalphaFc) is a fully human recombinant fusion protein that blocks the CD47-SIRPalpha axis by binding to human CD47 and enhancing phagocytosis of malignant cells..These data indicate that TTI-621 is active across a broad range of human tumors. PMID: 27856600
this review highlights the various functions of CD47, discusses anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborates on the clinical potential of CD47 blockade. PMID: 28077173
we observed neutrophilic infiltration was slightly increased in anti-CD47 treated tumors compared to IgG control. PMID: 28100392
In pulmonary hypertension TSP1-CD47 is upregulated, and contributes to pulmonary arterial vasculopathy and dysfunction. PMID: 27742621
thrombospondin-1 via CD47 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation/self-renewal. PMID: 27259369
Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation PMID: 28522599
the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading. PMID: 27349907
Results indicated that surgical resection combined with anti-CD47 blocking immunotherapy promoted an inflammatory response and prolonged survival in xenograft animal model, and is therefore an attractive strategy for clinical translation. PMID: 28076333
Results show that the stronger expression of CD47 by cancer cells and larger number of total macrophages/M2 were independently related to shorter survivals. PMID: 27322955
Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a primate model is associated with an immune modulating effect, leading to markedly prolonged survival of donor swine skin xenografts. PMID: 27232934
CD47 is a promising cancer biomarker, and targeting CD47 presents an effective and potential therapeutic strategy through synthesized mechanisms PMID: 26446381
CD47 seems to mediate fusion mostly through broad contact surfaces between the partners' cell membrane while syncytin-1 mediate fusion through phagocytic-cup like structure. PMID: 27714815
The results suggested a critical role of CD47 in laryngeal squamous cell carcinoma development. PMID: 27855370
Data show that anti-human CD47 antibody B6H12 decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factors. PMID: 26840086
suggest that microglial activation may be partially caused by CD47/signal regulatory protein-alpha- and CD200/CD200R-mediated reductions in the immune inhibitory pathways PMID: 27095555
Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy. PMID: 27091975
Data suggest a reduction in the CD47 antigen/signal-regulatory protein alpha (SIRPalpha) pathway by programmed cell death protein 1 (PD-1) blockade, which regulates Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). PMID: 26573233
atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or 'efferocytosis' PMID: 27437576
CD47 is a critical regulator in the metastasis of osteosarcoma and results suggest that targeted inhibition of this antigen by anti-CD47 may be a novel immunotherapeutic approach in the management of this tumor. PMID: 26093091
agents that block the CD47:SIRP-alpha engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo PMID: 26116271
CD47 is an adverse prognostic factor and promising therapeutic target in gastric cancer. PMID: 26077800
study demonstrates that antigen-presenting cells(CD47+) in coculture with human macrophages show a CD47 concentration-dependent inhibition of phagocytosis PMID: 25593301
CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1. PMID: 26512116
CD47 is highly expressed on cancer stem cells, but not on other nonmalignant cells in the pancreas. PMID: 25717063
CD47 mediates signaling from the extracellular matrix that coordinately regulates basal metabolism and cytoprotective responses to radiation injury PMID: 26311851
CD47 has a central role in hydrogen sulfate biosynthesis, regulation and signaling in T cells. PMID: 25747479
Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages. PMID: 26085683
While CD47 expression on circulating AML blasts has been shown to be a negative prognostic marker for a very defined population of AML patients with NK AML, CD47 expression on AML BM blasts is not PMID: 25943033
Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis PMID: 25837251
during translation of CD47, the scaffold function of the 3' UTR facilitates binding of proteins to nascent proteins, to direct their transport or function--and this role of 3' UTRs can be regulated by polyadenylation PMID: 25896326
Report poor prognosis/survival in luminal breast cancer patients with circulating tumor cells co-expressing MET and CD47. PMID: 25230070
Staphylococcal SElX and SSL6 proteins bind cell surface receptors PSGL-1 and CD47, respectively. PMID: 24840181
The thrombospondin-1 receptor CD47 directly or indirectly regulates intercellular communication mediated by the transfer of extracellular vesicles between vascular cells. PMID: 24887393
expression is induced following EBV infection of B cells; ligation cases G1 arres PMID: 24911792
CD47 regulates the epigenetic code by targeting UHRF1. PMID: 25550546
Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells. PMID: 25001859
the TSP-derived 4N1K peptide effects on cell adhesion and integrin activation are independent of CD47 PMID: 24848268
CD47 associates with and regulates VEGFR2 in T cells. CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of vascular endothelial growth factor by T cells contributes to this regulation. PMID: 25200950
Suppression of CD47 by morpholino approach suppressed growth of hepatocellular carcinoma in vivo and exerted a chemosensitization effect through blockade of CTSS/PAR2 signaling. PMID: 24523067
CD47 plays the pivotal role in the immune evasion of primary effusion lymphoma cells in body cavities. Therapeutic antibody targeting of CD47 could be an effective therapy for PEL. PMID: 24726056
Data indicate that CD47 in cis interactions regulate LFA-1 (integrin alphaLbeta2) and VLA-4 (integrin alpha4beta1) integrin affinity, and this process plays a substantial role in the adhesion of T-cells. PMID: 24006483

Hide All

Subcellular Location

Cell membrane; Multi-pass membrane protein.

Tissue Specificity

Very broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain.

Database Links

HGNC: 1682

OMIM: 601028

KEGG: hsa:961

STRING: 9606.ENSP00000355361

UniGene: Hs.446414

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA004940MA1HU
Size	$49.9
	Order now
Promotion
Image	The Binding Activity of Human CD47 with Anti-CD47 recombinant antibody Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CD47 (CSB-MP004940HUd7) at 2 μg/mL can bind Anti-CD47 recombinant antibody. The EC₅₀ is 1.343-1.561 ng/mL. Untransfected CT26 cells (green line) and transfected Human DLL3 & CD47 CT26 stable cells (red line) were stained with anti-CD47 antibody (CSB-RA004940MA1HU) (2µg/110⁶cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry. Untransfected CT26 cells (green line) and transfected Human DLL3 & CD47 CT26 stable cells (red line) were stained with anti-DLL3 antibody (CSB-RA882142MA2HU) (2µg/110⁶cells), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
Have Questions?	Leave a Message or Start an on-line Chat

CD47 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background